Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

eTheRNA immunotherapies joins forces with Ghent University

2
SHARES

eTheRNA has announced a collaboration and license agreement with renowned Belgian research institution, Ghent University.

Research partnership

eTheRNA immunotherapies NV (eTheRNA), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, has announced a partnership with Ghent University. Established in 2013, the company is headquartered in Belgium and aims to become a world-leading company in the RNA field.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Under the terms of the agreement, eTheRNA will receive exclusive worldwide rights to commercialise a new library of novel ionisable lipids, co-developed with the research group led by Professor Bruno De Geest at Ghent University, for the development of lipid nanoparticle (LNP) formulations. Ionisable lipids are a main driver of LNP activity, enhancing the entrapment and stabilisation of mRNA into the LNP and facilitating the release of the mRNA payload into the cell cytoplasm where the mRNA is subsequently translated into the protein of interest.

The ionisable lipids in the new library have been designed for improved biodegradability and thus offer a better safety profile. Furthermore, LNPs formulated with these ionisable lipids are expected to have favourable thermostability properties, reducing the need for cold chain storage of the final product.

“One of the bottlenecks with current mRNA pharmaceuticals is the need for elaborate cold-chain logistics,” said Steven Powell, CEO at eTheRNA. “This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles. The new ionisable lipids with improved properties will provide the basis for our second generation of LNPs that will be used to develop future prophylactic vaccines and tumour microenvironment-modulating therapies.”

“This partnership is the result of continuing efforts by Ghent University and Ghent University Hospital to become a leading academic and clinical centre for the development of advanced therapy medicinal products (ATMPs),” Dr Dominic De Groote at Ghent University added.

More information can be found here.

Share via
Share via